Latest Development Program News

Titan Minerals has reported significant wide zones of gold-silver-copper porphyry mineralisation at its Kaliman target within the Dynasty Gold Project, following a 25,000m drilling campaign in 2025. This breakthrough is set to underpin an imminent Mineral Resource update expected in late Q1 2026.

ABx Group has secured partnerships in two major Australian Government R&D initiatives aimed at advancing rare earths refining and exploration technologies, accelerating development of its ionic clay rare earth project in Tasmania.

ADX Energy has secured a crucial extension on its loan note repayments, unlocking financial flexibility to advance multiple drilling and development projects across Austria and Italy.

Dimerix Limited has completed dosing of the last adult patient in its ACTION3 Phase 3 trial for DMX-200, exceeding its recruitment target and setting the stage for key regulatory milestones.

Metal Bank reports exceptional gold recovery results from its Seven Leaders Prospect near Kalgoorlie, highlighting a 72.5% gravity recovery and over 99% leaching efficiency, underpinning its near-term production ambitions.

BluGlass has embarked on a A$1.25 million development program with a major US defence prime, receiving an initial A$560,000 order to develop cutting-edge visible GaN lasers for aerospace and defence applications.

Tivan Limited has committed up to $1 million over four years to support Indigenous communities through a partnership with the Central Land Council, reinforcing its responsible mining approach in Central Australia.

Provaris Energy has successfully raised $1.325 million through an oversubscribed placement, aiming to advance its 2026 development milestones in hydrogen and carbon dioxide storage technologies.

Aurum Resources reports multiple broad, shallow, high-grade gold intercepts from its 30,000m drilling program at the Napié Gold Project in Côte d’Ivoire, underpinning an imminent resource update and growth strategy. The company’s dual-asset approach and strong balance sheet position it for a pivotal transition from explorer to developer in 2026.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

PYC Therapeutics has successfully closed its retail entitlement offer, raising approximately $47 million at $1.50 per new share with a 40% take-up rate. New shares are set to begin trading on the ASX from 9 March 2026.

Cobalt Blue Holdings has confirmed its cobalt sulphate meets stringent battery precursor specifications, advancing its Kwinana Cobalt Refinery toward a Final Investment Decision. The company also expands its graphite recovery program, positioning itself at the forefront of Australia’s battery materials ecosystem.